FindTrial
Sign In

Direct sputum sensitivity testing (DSST) in cystic fibrosis

Direct sputum sensitivity testing (DSST) in cystic fibrosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN61821827
Enrollment
Unknown
Registered
2003-09-12
Start date
2001-04-01
Completion date
Unknown
Last updated
2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis Nutritional, Metabolic, Endocrine Cystic fibrosis

Interventions

Double blind, randomised controlled trial of DSST versus usual antibiotic sensitivity testing in cystic fibrosis patients with infective exacerbations requiring IV antibiotics.

Sponsors

Department of Health (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cystic fibrosis patients (with infective exacerbations requiring IV antibiotics) who are colonised with Pseudonomas or Burkholderia.

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

MeasureTime frame
Duration of IV antibiotic therapy.—

Secondary

MeasureTime frame
1. Lung function 2. Quality of life 3. Antibiotic drug costs.—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026